#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	) Group Art Unit: N/A
Se Hwan YANG et al.	) Examiner: N/A
Serial No.: N/A (National phase of PCT/KR2004/002474)	) Filed: Herewith
For: METHOD FOR MASS PRODUCTION OF HUMAN FOLLICLE STIMULATING HORMONE	) Confirmation No.: N/A
Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	

### INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are attached

English Language Patent Document:

A1. U.S. 2001/0007757 A1, July 12, 2001

#### English Language Non-Patent Documents:

record as cited references in the application.

- C1. MANNAERTS et al., "Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone," Endocrinology, 129:2623-2630 (1991) (Abstract only)
- C2. LOUMAYE et al., "Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility," Human Reproduction Update 4(6):862-881 (1998)
- C3. OLIJVE et al., "Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)," Molecular Human Reproduction, 2(5):371-382 (1996) C4. GEBERT and GRAY, "Expression of FSH in CHO cells. I. Comparison of promoter types
- and effects of their respective inducers," Cytotechnology, 14:39-45 (1994)
  CS. KEENE et al., "Expression of BiologicalPy Active Human Follitropin in Chinese Hamster
  Ovary Cells," Journal of Biological Chemistry, 26409-4769-4775 (1989)
- It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of

The present application is a national stage of international application number PCT/KR2004/002474, filed September 24, 2004 and copies of the published application (Publication Number, WO 2005/030969 A1) and the International Search Report are attached herewith.

The Commissioner is hereby authorized to charge JHK Law's Deposit Account No. 502486 for such fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. 502486.

## Respectfully submitted,

March 22, 2006 Date /Joseph Hyosuk Kim/ Joseph Hyosuk Kim, Ph.D. Reg. No. 41,425 Attorney for Applicants

JHK Law P.O. Box 1078 La Canada, CA 91012-1078 Telephone: (818) 249-8177 Facsimile: (818) 249-8277

PTO/SB/088 (08-03)

Approved for use through 07/31/2005, OMB 0551-0031

Under the Paperwork Red	ucton A	at of 1995, no persons ar		of information unless it contains a valid OMB control number
Substitute for form 1449/PTO				Complete if Known
			Application Number	National phase of PCT/KR2004/002474
INFORMATION				Herewith
STATEMENT E	BY A	PPLICANT		YANG, Se Hwan
(Use as many sheets as necessary)		Art Unit	N/A	
,			Examiner Name	N/A
Sheet 1	of	1	Attorney Docket Number	58049-00025

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serail, symposium, calaige, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	MANNAERTS et al., "Comparative in vitro and in vivo studies on the biological characteristics of recombinant human folicle-atimulating hormone," Endocrinology, 129:2623-2630 (1991) (Abstract only)	
	C2	LOUMAYE et al., "Recombinant foliole stimulating hormone: development of the first biotechnology product for the treatment of infertility," Human Reproduction Update 4(6):862-881 (1998)	
	СЗ	OLIJVE et al., "Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)," Molecular Human Reproduction, 2(5):371-382 (1996)	
	C4	GEBERT and GRAY, "Expression of FSH in CHO cells, I. Comparison of promoter types and effects of their respective inducers," Cytotechnology, 14:39-45 (1994)	
	C5	KEENE et al., "Expression of Biologically Active Human Follitropin in Chinese Hamster Ovary Cells," Journal of Biological Chemistry, 264(9):4769-4775 (1989)	

Examiner Signature		Date Considered	8.5
*EXAMINER: In	that if reference considered, whether or not citation is in conformance with MPEP 60	Draw line through o	tation if not in conformance and not

informance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unque citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to fire (and by the USPTO Into processor or information is required by 35 CFR 196. The anomation is required to document a become by the purpose which is to recovers) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 194. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2009, OMB 0651-0051 U.S. Petent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE lection of information unless it contains a valid OMB control number.

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to re	spond to a cof
Substitute for form 1449/PTO	
	Application

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 1

Number National Phase of PCT/KR2004/002474 Filing Date Herewith Fird Named Inventor YANG. Se Hwan Art Unit Examiner Name Attorney Docket Number 58049-00025

			U. S. PATEN	T DOCUMENTS	
Examiner Cita Initials* No.1	Cite No.	Document Number	Publication Data MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Pessages or Relevant
	Number-Kind Code <sup>2 (Finner)</sup>		**	Figures Appear	
	A1	US- 2001/0007757 A1	07-12-2001	Boirne et al.	whole document
		US-			
		US			
		US-		1	
		US-	_		
		US-			

Examiner initials'	No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Otted Document	Peges, Columns, Lines, Where Relevant Pessages Or Relevant Figures Appear	П
		Country Code <sup>2</sup> Number <sup>6</sup> Ward Code <sup>2</sup> (Flanows)	MM-DD-YYYY			76
						ш
						ㅁ
						ш
		_				

Considered Signeture

"EXAMPLE: India if reference considered, whether or not obtains in conformance with MPEP 600. Draw line through citation if not in conformance and not considered finishs copy of this form with next commissection to applicant's septicant's septicant and exception number (options). "See Kinds Codes of UNIFOP Developments at view surprising, or WHEFE DRIVE." Either Cities that insured the document, by the horistics now WHEFE District Cities in Insured to document, by the horistics now WHEFE Districted CTTs, "For Jugareses patient document, the Activation of the year of the region of the Emperor must preced the small number of the patient document. "Kind of document to the appropriate symptotic so indicated on the document under WHEFE Districted STs in Fig. 19 possible." "Regions is to place a check man the next Empfire Improved." Translation is attached

TO: Commissioner for Patants, P.O. Box 1459, Alexandria, VA 22913-1459.

If you need assistance in completing the form. cell 1-800-PTO-9199 (1-800-786-9199) and select option 2